Meeting the Challenge of Eliminating Chronic Hepatitis B Infection
AbstractOver 257 million people live with chronic hepatitis B virus (HBV) infection and there is no known cure. The effective preventative vaccine has no impact on existing infection. Despite the existence of drugs which efficiently suppress viral replication, treatment is usually life-long and finite therapies that cure HBV infection are urgently required. However, even if such therapies were available today, it is unlikely they would reach all of those who need it most, due to chronic hepatitis B (CHB) being largely undiagnosed across the globe and to the dire need for health systems promoting access to therapy. Considerable challenges to developing and implementing an effective HBV cure remain. Nonetheless, important advances towards a cure are being made, both in the development of a multitude of new therapeutic agents currently undergoing clinical trials, and through the establishment of a new global initiative dedicated to an HBV cure, ICE-HBV, that is working together with existing organisations to fast-track an HBV cure available to all.
Share & Cite This Article
Revill, P.A.; Penicaud, C.; Brechot, C.; Zoulim, F. Meeting the Challenge of Eliminating Chronic Hepatitis B Infection. Genes 2019, 10, 260.
Revill PA, Penicaud C, Brechot C, Zoulim F. Meeting the Challenge of Eliminating Chronic Hepatitis B Infection. Genes. 2019; 10(4):260.Chicago/Turabian Style
Revill, Peter A.; Penicaud, Capucine; Brechot, Christian; Zoulim, Fabien. 2019. "Meeting the Challenge of Eliminating Chronic Hepatitis B Infection." Genes 10, no. 4: 260.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.